EA026384B1 - Лечение заболеваний сердца - Google Patents

Лечение заболеваний сердца Download PDF

Info

Publication number
EA026384B1
EA026384B1 EA201290540A EA201290540A EA026384B1 EA 026384 B1 EA026384 B1 EA 026384B1 EA 201290540 A EA201290540 A EA 201290540A EA 201290540 A EA201290540 A EA 201290540A EA 026384 B1 EA026384 B1 EA 026384B1
Authority
EA
Eurasian Patent Office
Prior art keywords
agd
azr
compound
zeg
tug
Prior art date
Application number
EA201290540A
Other languages
English (en)
Russian (ru)
Other versions
EA201290540A1 (ru
Inventor
Йорген Соберг Петерсен
Анна Луиза Кьёлби
Мари Сковгаард
Хенрик Дьюлунд Педерсен
Лене Аксельсен
Дитте Рибер
Эдди Мейер
Рие Шультц Хансен
Келд Фосгерау
Бьярне Дью Ларсен
Original Assignee
Зилэнд Фарма А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43928934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA026384(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Зилэнд Фарма А/С filed Critical Зилэнд Фарма А/С
Publication of EA201290540A1 publication Critical patent/EA201290540A1/ru
Publication of EA026384B1 publication Critical patent/EA026384B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EA201290540A 2010-01-20 2011-01-20 Лечение заболеваний сердца EA026384B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29665710P 2010-01-20 2010-01-20
PCT/DK2011/050018 WO2011088837A1 (en) 2010-01-20 2011-01-20 Treatment of cardiac conditions

Publications (2)

Publication Number Publication Date
EA201290540A1 EA201290540A1 (ru) 2013-03-29
EA026384B1 true EA026384B1 (ru) 2017-04-28

Family

ID=43928934

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290540A EA026384B1 (ru) 2010-01-20 2011-01-20 Лечение заболеваний сердца

Country Status (15)

Country Link
US (1) US20130157953A1 (https=)
EP (1) EP2525809B1 (https=)
JP (2) JP2013517307A (https=)
KR (1) KR20120128129A (https=)
CN (1) CN102892425A (https=)
AU (1) AU2011206979B2 (https=)
BR (1) BR112012018104A2 (https=)
CA (1) CA2786934A1 (https=)
CL (1) CL2012002037A1 (https=)
EA (1) EA026384B1 (https=)
IL (1) IL220876A0 (https=)
MX (1) MX342409B (https=)
NZ (1) NZ601167A (https=)
PH (1) PH12012501494A1 (https=)
WO (1) WO2011088837A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110126592A (ko) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
WO2010070255A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
US8685919B2 (en) 2008-12-15 2014-04-01 Zealand Pharma A/S Glucagon analogues
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
EA023925B1 (ru) 2010-04-27 2016-07-29 Зилэнд Фарма А/С Пептидные конъюгаты агонистов рецептора glp-1 и их применение
UY33462A (es) * 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
PH12012502472A1 (en) 2010-06-24 2013-03-25 Zealand Pharma As Glucagon analogues
MX2014005351A (es) 2011-11-03 2014-05-28 Zealand Pharma As Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
WO2013092703A2 (en) * 2011-12-23 2013-06-27 Zealand Pharma A/S Glucagon analogues
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
AU2013295035B2 (en) 2012-07-23 2017-08-03 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN104918961A (zh) * 2012-11-20 2015-09-16 梅德瑞斯糖尿病有限责任公司 用于胰岛素抗性的改良的肽药物
JP2016503046A (ja) * 2012-12-19 2016-02-01 ノヴォ ノルディスク アー／エス コレステロール流出活性を有する新規ｇｌｐ−１受容体アゴニスト
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
SI2986313T1 (sl) 2013-04-18 2019-09-30 Novo Nordisk A/S Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
MX2016005556A (es) * 2013-11-06 2016-07-15 Zealand Pharma As Compuestos agonistas duales de gip-glp-1 y procedimientos.
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
CN103724424B (zh) * 2013-12-27 2015-05-27 浙江省农业科学院 一种mPEG-SPA-pGLP-2复合物及其制备方法和应用
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
ES2805326T3 (es) * 2014-10-10 2021-02-11 Novo Nordisk As Coagonistas estables del receptor de GLP-1/glucagón basados en GLP-1
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
MY185334A (en) 2014-12-30 2021-05-06 Hanmi Pharm Ind Co Ltd Glucagon derivatives with improved stability
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
WO2016168388A2 (en) * 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
EA201890058A1 (ru) 2015-06-30 2018-07-31 Ханми Фарм. Ко., Лтд. Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
WO2017116204A1 (ko) 2015-12-31 2017-07-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
EP3468569A4 (en) 2016-06-09 2020-05-27 AmideBio LLC GLUCAGON ANALOG AND METHOD FOR USE THEREOF
KR102005457B1 (ko) 2016-06-29 2019-07-30 한미약품 주식회사 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
AU2017371516C1 (en) 2016-12-09 2021-09-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
CN120887972A (zh) * 2017-11-24 2025-11-04 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物
CN116143939A (zh) * 2017-11-24 2023-05-23 浙江道尔生物科技有限公司 一种治疗代谢疾病的多重活性蛋白
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
BR112020013644A2 (pt) 2018-01-03 2020-12-01 Mederis Diabetes, Llc produto de peptídeo ou sal farmaceuticamente aceitável do mesmo para uso no tratamento de síndrome de ovário policístico, um distúrbio renal ou um distúrbio hepático, e, kit.
WO2021083306A1 (zh) * 2019-10-31 2021-05-06 东莞市东阳光生物药研发有限公司 Glp-1/gcg双受体激动剂多肽
EP3842060A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
KR102886870B1 (ko) * 2020-05-09 2025-11-18 톈진 인스티튜트 오브 파마슈티컬 리서치 씨오., 엘티디. 이중 수용체 아고니즘 작용을 갖는 폴리펩티드 유도체 및 그 용도
US12171806B2 (en) 2021-09-28 2024-12-24 Spitfire Pharma Llc Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034285A2 (en) * 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
EP1421950A1 (en) * 2002-11-19 2004-05-26 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
WO2008152403A1 (en) * 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE366115T1 (de) * 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc Inotropische und diuretische effekte von exendin und glp-1
JP4394279B2 (ja) 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
CN101389648B (zh) 2006-02-22 2013-07-17 默沙东公司 肽胃泌酸调节素衍生物
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
AU2008216265B2 (en) * 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2300037B1 (en) * 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2009155257A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
WO2010107487A2 (en) * 2009-03-18 2010-09-23 Wu Nian Lipid-drug conjugates for drug delivery
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
WO2002034285A2 (en) * 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
EP1421950A1 (en) * 2002-11-19 2004-05-26 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
WO2008152403A1 (en) * 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GILLIAN L. SOWDEN, DANIEL J. DRUCKER, DAVID WEINSHENKER, STEVEN J. SWOAP: "Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor", AMERICAN JOURNAL OF PHYSIOLOGY: REGULATORY, INTEGRATIVE AND COMPARATIVE PHYSIOLOGY., AMERICAN PHYSIOLOGICAL SOCIETY., US, vol. 292, no. 2, 1 February 2007 (2007-02-01), US, pages R962 - R970, XP002637634, ISSN: 0363-6119, DOI: 10.1152/ajpregu.00405.2006 *
GRIEVE D J, CASSIDY R S, GREEN B D: "Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: Potential therapeutic benefits beyond glycaemic control?", BRITISH JOURNAL OF PHARMACOLOGY, WILEY-BLACKWELL, UK, vol. 157, no. 8, 1 January 2009 (2009-01-01), UK, pages 1340 - 1351, XP002637632, ISSN: 0007-1188, DOI: 10.1111/J.1476-5381.2009.00376.X *
MAYER S E, NAMM D H, RICE L R: "EFFECT OF GLUCAGON ON CYCLIC 3 5 AMP PHOSPHORYLASE ACTIVITY AND CONTRACTILITY OF HEART MUSCLE OF THE RAT", CIRCULATION RESEARCH., GRUNE AND STRATTON, BALTIMORE, US, vol. 26, no. 2, 1 January 1970 (1970-01-01), US, pages 225 - 233, XP002637631, ISSN: 0009-7330 *
ROBBERECHT, P. ; WAELBROECK, M. ; CAMUS, J.-C. ; DE NEEF, P. ; COY, D.H. ; CHRISTOPHE, J.: "Comparative efficacy of seven synthetic glucagon analogs, modified in position 1, 2 and/or 12, on liver and heart adenylate cyclase from rat", PEPTIDES, ELSEVIER, AMSTERDAM, NL, vol. 7, 1 January 1986 (1986-01-01), AMSTERDAM, NL, pages 109 - 112, XP023486854, ISSN: 0196-9781, DOI: 10.1016/0196-9781(86)90172-5 *
SARACENI CHRISTINE; BRODERICK TOM L: "Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function.", DRUGS IN R & D, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 8, no. 3, 1 January 2007 (2007-01-01), NZ, pages 145 - 153, XP009095298, ISSN: 1174-5886, DOI: 10.2165/00126839-200708030-00002 *
UESAKA TOSHIHIRO, ET AL: "Glucagon-like peptide isolated from the eel intestine: Effects on atrial beating", JOURNAL OF EXPERIMENTAL BIOLOGY., COMPANY OF BIOLOGISTS, CAMBRIDGE, GB, vol. 204, no. 17, 1 September 2001 (2001-09-01), GB, pages 3019 - 3026, XP002637633, ISSN: 0022-0949 *

Also Published As

Publication number Publication date
CL2012002037A1 (es) 2012-09-07
CA2786934A1 (en) 2011-07-28
WO2011088837A1 (en) 2011-07-28
IL220876A0 (en) 2012-09-24
CN102892425A (zh) 2013-01-23
JP2013517307A (ja) 2013-05-16
MX2012008440A (es) 2012-08-15
AU2011206979B2 (en) 2015-09-10
BR112012018104A2 (pt) 2017-10-17
EA201290540A1 (ru) 2013-03-29
EP2525809A1 (en) 2012-11-28
KR20120128129A (ko) 2012-11-26
EP2525809B1 (en) 2016-08-03
US20130157953A1 (en) 2013-06-20
AU2011206979A1 (en) 2012-08-02
JP2016138127A (ja) 2016-08-04
JP6200025B2 (ja) 2017-09-20
NZ601167A (en) 2014-12-24
MX342409B (es) 2016-09-28
PH12012501494A1 (en) 2012-10-22

Similar Documents

Publication Publication Date Title
EA026384B1 (ru) Лечение заболеваний сердца
US9403894B2 (en) Glucagon analogues
US8642540B2 (en) Glucagon analogues
US8642541B2 (en) Glucagon analogues
US8680049B2 (en) Glucagon analogues
EA020537B1 (ru) Аналоги глюкагона
CN104144696A (zh) 胰高血糖素类似物
JP6006264B2 (ja) グルカゴン類似体
JP5912150B2 (ja) グルカゴン類似体
JP2014210799A (ja) グルカゴン類似体
OA16287A (en) Glucagon analogues.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM